Herpes%20simplex%20virus%20infection Signs and Symptoms

Signs and Symptoms

Definition

Primary Herpes Simplex Virus (HSV) Infection

1st infection with either herpes simplex virus-1 (HSV-1) or herpes simplex virus-2 (HSV-2) in individuals who do not have antibodies to either HSV-1 or HSV-2

First Episode - Nonprimary Infection

Infection with either HSV-1 or HSV-2 in individuals who have previously existing antibodies against HSV-1 or HSV-2 respectively

Recurrent Herpes Simplex Virus (HSV) Infection

Results from reactivation of latent virus
Usually brought about by triggering factors eg ultraviolet (UV) light, immunosuppression, trauma, stress, febrile illness
Less severe and becomes less frequent with time

Epidemiology

Globally, HSV-1 infection affects approximately 3.7 billion individuals under 50 years of age, and approximately 491 million in 15 to 49-year-old-individuals are infected with HSV-2

Transmission

Direct contact with sores, saliva or areas around the mouth of actively shedding individuals encourage transmission of HSV-1; incubation period ranges from 2-12 days
HSV-2 virus is typically transmitted during sexual intercourse through direct contact of genital or anal surfaces, skin, sores or fluids

Optimizing metastatic hormone-sensitive prostate cancer treatment in advanced prostate cancer

Assoc Prof. Darren Poon, Assoc Prof. Edmund Chiong, 14 Jan 2021

Metastatic hormone-sensitive prostate cancer (mHSPC) refers to the condition whereby patients have metastatic prostate cancer and no prior hormonal therapy or androgen deprivation therapy (ADT). Typically, patients with mHSPC have been treated with ADT alone, following which, the overwhelming majority develop castration resistance over time and head towards eventual mortality. In recent years, the publication of various landmark trials has prompted dramatic changes in the mHSPC treatment landscape, and had favourably impacted overall survival (OS) in these patients. At a recent webinar, A/Prof Darren Poon, Honorary Consultant in Clinical Oncology, Hong Kong Sanatorium & Hospital, and Honorary Clinical Associate Professor, Department of Clinical Oncology, The Chinese University of Hong Kong, reviewed treatment options in mHSPC, while A/Prof Edmund Chiong, Head and Senior Consultant, Department of Urology, National University Hospital, Singapore, presented a case which was discussed by an esteemed panel of experts. This webinar was jointly organized by the Singapore Society of Oncology and the Singapore Urological Association, and supported by Astellas.